Arabic Arabic English English French French German German
dark

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®

Biomica Ltd. today announced that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept (POC), Phase I clinical trial of Biomica’s drug candidate BMC-128 in patients with Non-Small Cell Lung Cancer (NSCLC). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Next Post

New Peripheral Vascular Microcatheters Save Procedure Time and Advance Treatment Capabilities

Related Posts
Total
0
Share